Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication ...

There is a simple discount patient access scheme for vadadustat. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact enquiries@medice ...

The appraisal committee has prepared final draft guidance (FDG) on Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821] and submitted it to NICE.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the vadadustat being ...

The evaluation committee considered evidence submitted by MEDICE, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

Vadadustat is recommended, within its marketing authorisation, as an option for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Vadadustat is only ...

Vadadustat (Vafseo) is available on the NHS. It is a possible treatment for symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Your healthcare professionals ...

Tools to help you put the guidance into practice.